GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Biodesix Inc (NAS:BDSX) » Definitions » Piotroski F-Score

Biodesix (Biodesix) Piotroski F-Score : 4 (As of May. 05, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Biodesix Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Biodesix has an F-score of 4 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Biodesix's Piotroski F-Score or its related term are showing as below:

BDSX' s Piotroski F-Score Range Over the Past 10 Years
Min: 3   Med: 4   Max: 4
Current: 4

During the past 6 years, the highest Piotroski F-Score of Biodesix was 4. The lowest was 3. And the median was 4.


Biodesix Piotroski F-Score Historical Data

The historical data trend for Biodesix's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biodesix Piotroski F-Score Chart

Biodesix Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Piotroski F-Score
Get a 7-Day Free Trial N/A N/A 3.00 4.00 4.00

Biodesix Quarterly Data
Dec18 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.00 4.00 3.00 4.00 4.00

Competitive Comparison of Biodesix's Piotroski F-Score

For the Diagnostics & Research subindustry, Biodesix's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biodesix's Piotroski F-Score Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Biodesix's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Biodesix's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Net Income was -18.702 + -13.356 + -10.949 + -9.139 = $-52.15 Mil.
Cash Flow from Operations was -7.686 + 0.937 + -3.838 + -12.283 = $-22.87 Mil.
Revenue was 9.056 + 11.872 + 13.491 + 14.668 = $49.09 Mil.
Gross Profit was 5.887 + 8.634 + 10.262 + 11.294 = $36.08 Mil.
Average Total Assets from the begining of this year (Dec22)
to the end of this year (Dec23) was
(92.906 + 80.793 + 77.623 + 86.786 + 99.096) / 5 = $87.4408 Mil.
Total Assets at the begining of this year (Dec22) was $92.91 Mil.
Long-Term Debt & Capital Lease Obligation was $60.39 Mil.
Total Current Assets was $39.68 Mil.
Total Current Liabilities was $33.42 Mil.
Net Income was -15.586 + -15.824 + -13.699 + -20.338 = $-65.45 Mil.

Revenue was 6.548 + 10.95 + 11.107 + 9.607 = $38.21 Mil.
Gross Profit was 3.313 + 6.97 + 7.474 + 6.301 = $24.06 Mil.
Average Total Assets from the begining of last year (Dec21)
to the end of last year (Dec22) was
(76.097 + 61.651 + 75.229 + 63.198 + 92.906) / 5 = $73.8162 Mil.
Total Assets at the begining of last year (Dec21) was $76.10 Mil.
Long-Term Debt & Capital Lease Obligation was $30.26 Mil.
Total Current Assets was $53.33 Mil.
Total Current Liabilities was $22.84 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Biodesix's current Net Income (TTM) was -52.15. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Biodesix's current Cash Flow from Operations (TTM) was -22.87. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec22)
=-52.146/92.906
=-0.56127699

ROA (Last Year)=Net Income/Total Assets (Dec21)
=-65.447/76.097
=-0.86004705

Biodesix's return on assets of this year was -0.56127699. Biodesix's return on assets of last year was -0.86004705. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Biodesix's current Net Income (TTM) was -52.15. Biodesix's current Cash Flow from Operations (TTM) was -22.87. ==> -22.87 > -52.15 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec22 to Dec23
=60.388/87.4408
=0.69061582

Gearing (Last Year: Dec22)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec21 to Dec22
=30.258/73.8162
=0.40991002

Biodesix's gearing of this year was 0.69061582. Biodesix's gearing of last year was 0.40991002. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec23)=Total Current Assets/Total Current Liabilities
=39.683/33.416
=1.18754489

Current Ratio (Last Year: Dec22)=Total Current Assets/Total Current Liabilities
=53.334/22.839
=2.33521608

Biodesix's current ratio of this year was 1.18754489. Biodesix's current ratio of last year was 2.33521608. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Biodesix's number of shares in issue this year was 92.436. Biodesix's number of shares in issue last year was 57.553. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=36.077/49.087
=0.73496038

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=24.058/38.212
=0.6295928

Biodesix's gross margin of this year was 0.73496038. Biodesix's gross margin of last year was 0.6295928. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec22)
=49.087/92.906
=0.52835124

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec21)
=38.212/76.097
=0.50214857

Biodesix's asset turnover of this year was 0.52835124. Biodesix's asset turnover of last year was 0.50214857. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+1+1+0+0+0+1+1
=4

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Biodesix has an F-score of 4 indicating the company's financial situation is typical for a stable company.

Biodesix  (NAS:BDSX) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Biodesix Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Biodesix's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Biodesix (Biodesix) Business Description

Traded in Other Exchanges
N/A
Address
2970 Wilderness Place, Suite 100, Boulder, CO, USA, 80301
Biodesix Inc is a data-driven diagnostic solutions company. Its artificial intelligence-based platform helps to discover, develop, and commercialize solutions for clinical unmet needs, with a focus on lung disease. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Coronavirus Disease 2019 (COVID-19) tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.
Executives
Scott Hutton director, officer: President & CEO 9965 FEDERAL DRIVE, COLORADO SPRINGS CO 80921
Kieran O'kane officer: Chief Commercial Officer 2970 WILDERNESS PLACE, SUITE 100, BOULDER CO 80301
Gary Anthony Pestano officer: Chief Development Officer 2970 WILDERNESS PLACE, SUITE 100, BOULDER CO 80301
Robin Harper Cowie officer: CFO, Sec'y & Treasurer 2970 WILDERNESS PLACE, SUITE 100, BOULDER CO 80301
Chris Vazquez officer: Chief Accounting Officer 2970 WILDERNESS PLACE, SUITE 100, BOULDER CO 80301
Jack W Schuler director, 10 percent owner 100 N. FIELD DRIVE, SUITE 360, LAKE FOREST IL 60045
Jon Faiz Kayyem director 5964 LA PLACE COURT, CARLSBAD CA 92008
Kennedy Lawrence T. Jr director, 10 percent owner C/O WESTWOOD MANAGEMENT, 1700 MADISON ROAD, SUITE 200, CINCINNATI OH 45206
Ryan H Siurek officer: Chief Accounting Officer 6200 SPRINT PARKWAY, OVERLAND PARK KS 66251
John Patience director, 10 percent owner, other: Chairman 28161 N. KEITH DRIVE, LAKE FOREST IL 60045
Matthew Strobeck director C/O METABOLIX, INC., 21 ERIE STREET, CAMBRIDGE MA 02139
Charles M Watts director 3950 SOUTH COUNTRY CLUB, SUITE 470, TUCSON AZ 85714
Hany Massarany director 1910 INNOVATION PARK DR, TUCSON AZ 85737
Georgantas Robert William Iii director, officer: SVP, Rsrch & Trans'l Science 2970 WILDERNESS PLACE, SUITE 100, BOULDER CO 80301
Jean M. Franchi director C/O DIMENSION THERAPEUTICS, INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139